Trust Company of Vermont’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Trust Company of Vermont’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-204	Closed	-$25	–	906
2023 Q4	$25	Hold	204	–	–	﹤0.01%	798
2023 Q3	$19	Hold	204	–	–	﹤0.01%	810
2023 Q2	$73	Hold	204	–	–	﹤0.01%	819
2023 Q1	$73	Hold	204	–	–	﹤0.01%	863
2022 Q4	$181	Hold	204	–	–	﹤0.01%	844
2022 Q3	$0	Hold	204	–	–	﹤0.01%	1046
2022 Q2	$0	Buy	+204	New	+$353	﹤0.01%	922
2022 Q1	–	Sell	-204	Closed	-$1K	–	786
2021 Q4	$1K	Buy	+204	New	+$1.27K	﹤0.01%	798
2021 Q3	–	Sell	-204	Closed	-$2K	–	758
2021 Q2	$2K	Hold	204	–	–	﹤0.01%	759
2021 Q1	$2K	Hold	204	–	–	﹤0.01%	729
2020 Q4	$1K	Hold	204	–	–	﹤0.01%	750
2020 Q3	$2K	Buy	+204	New	+$1.87K	﹤0.01%	717

Other funds holding SRNE

LCM

Lattice Capital Management Kirkland, Washington $56.9M AUM 49.15% 1-Year Est. Return

KLCM Advisors Milwaukee, Wisconsin $1.27B AUM 31.14% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

HCM

Highlander Capital Management Short Hills, New Jersey $292M AUM 22.24% 1-Year Est. Return

Trust Company of Vermont's SRNE Position: Q1 2024 in Review

Trust Company of Vermont sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2024, closing a stake of 204 shares — an estimated $25 sold.

Trust Company of Vermont first reported a position in SRNE in Q3 2020 and held it in 12 quarters. The position peaked at $2K in Q2 2021. 7 funds tracked by Wall St. Rank hold SRNE as of Q1 2024.

Trust Company of Vermont reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2024 after selling out during the quarter.
Trust Company of Vermont sold 204 Sorrento Therapeutics, Inc. shares in Q1 2024, an estimated $25.
Trust Company of Vermont first reported a position in Sorrento Therapeutics, Inc. in Q3 2020 and held it in 12 quarters.
Trust Company of Vermont's Sorrento Therapeutics, Inc. position peaked at $2K in Q2 2021.
7 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2024.

Based on Trust Company of Vermont's 13F filing for Q1 2024, filed 3 May 2024.